Vaccination of immunocompromised hosts

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 1243-1256

  Ljungman, Per ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902068735     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00016-1     Document Type: Chapter

References (340)

1. Kumar D., Michaels M.G., Morris M.I., et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010, 10:521-526.
2. Goossen G.M., Kremer L.C., van de Wetering M.D. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev 2009, 2. CD006484.
3. Ljungman P., Cordonnier C., Einsele H., et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009, 44:521-526.
4. Cordonnier C., Labopin M., Chesnel V., et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 2009, 48:1392-1401.
5. Danzinger-Isakov L., Kumar D. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009, 9(suppl 4):S258-S262.
6. Campbell A.L., Herold B.C. Immunization of pediatric solid-organ transplantation candidates: immunizations in transplant candidates. Pediatr Transplant 2005, 9:652-661.
7. Lin P.L., Michaels M.G., Green M., et al. Safety and immunogenicity of the American Academy of Pediatrics-recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 2005, 116:160-167.
8. Immunization in Special Clinical Circumstances. Red Book report of the Committee on Infectious Diseases 2009, American Academy of Pediatrics, Elk Grove Village, IL. 28th ed. L.K. Pickering (Ed.).
9. Lu C.C., Wang Y.C., Lai J.H., et al. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine 2011, 29:444-450.
10. Naqvi A., Fadoo Z., Alvi S. Vaccination guidelines for children with cancer and hematopoietic stem cell transplantation living in resource-poor countries. Pediatr Blood Cancer 2010, 54:3-7.
11. Savani B.N., Stratton P., Shenoy A., et al. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation: implications for screening and HPV vaccination. Biol Blood Marrow Transplant 2008, 14:1072-1075.
12. Klosky J.L., Gamble H.L., Spunt S.L., et al. Human papillomavirus vaccination in survivors of childhood cancer. Cancer 2009, 115:5627-5636.
13. Hajjar L.A., Mauad T., Galas F.R., et al. Severe novel influenza A (H1N1) infection in cancer patients. Ann Oncol 2010, 21:2333-2341.
14. Kumar D., Michaels M.G., Morris M.I., et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010, 10:521-526.
15. Launes C., Rives S., Catala A., et al. Pandemic influenza A (2009 H1N1) in children with acute lymphoblastic leukaemia. Br J Haematol 2010, 149:874-878.
16. Tramontana A.R., George B., Hurt A.C., et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010, 16:1068-1075.
17. Cost C., Brock E., Adams-Huet B., et al. 2009 pandemic influenza A (H1N1) virus infection in pediatric oncology and hematopoietic stem cell transplantation patients. Pediatr Blood Cancer 2011, 56:127-133.
18. Ljungman P., de La Camara R., Perez-Bercoff L., et al. Outcome of pandemic H1N1 infections in haematopoietic stem cell transplant recipients. Haematologica 2011, 96:1231-1235.
19. de Lavallade H., Garland P., Sekine T., et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011, 96:307-314.
20. Ljungman P., Nahi H., Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 2005, 130:96-98.
21. Feldman S., Malone W., Wilbur R., et al. Pneumococcal vaccination in children with leukemia. Med Pediatr Oncol 1985, 13:69-72.
22. Robertson J.D., Nagesh K., Jowitt S.N., et al. Immunogenicity of vaccination against influenza Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 2000, 82:1261-1265.
23. Levine A., Overturf G., Field R., et al. Use and efficacy of pneumococcal vaccine in patients with Hodgkin's disease. Blood 1979, 54:1171-1175.
24. Addiego J.J., Ammann A., Schiffman G., et al. Response to pneumococcal polysaccaride vaccine in patients with untreated Hodgkin's disease. Lancet 1980, 2:450-452.
25. Frederiksen B., Specht L., Henrichsen J., et al. Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease. Eur J Haematol 1989, 43:45-49.
26. Donaldson S., Vosti K., Berberich F., et al. Response to pneumococcal vaccine among children with Hodgkin's disease. Rev Infect Dis 1981, 3(suppl):S133-S143.
27. Grimfors G., Söderqvist M., Holm G., et al. A longitudinal study of class and subclass antibody response to pneumococcal vaccination in splenectomized individuals with special reference to patients with Hodgkin's disease. Eur J Haematol 1990, 45:101-108.
28. Landgren O., Bjorkholm M., Konradsen H.B., et al. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. J Intern Med 2004, 255:664-673.
29. Cherif H., Landgren O., Konradsen H.B., et al. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. Vaccine 2006, 24:75-81.
30. Molrine D.C., George S., Tarbell N., et al. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Ann Intern Med 1995, 123:828-834.
31. Sinisalo M., Vilpo J., Itala M., et al. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine 2007, 26:82-87.
32. Chan C.Y., Molrine D.C., George S., et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996, 173:256-258.
33. Feldman S., Gigliotti F., Shenep J., et al. Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis 1990, 161:926-931.
34. Ridgway D., Wolff L., Deforest A. Immunization response varies with intensity of acute lymphoblastic leukemia therapy. Am J Dis Child 1991, 145:887-891.
35. Shenep J.L., Fledman S., Gigliotti F., et al. Response of immunocompromised children with solid tumors to a conjugate vaccine for Haemophilus influenzae type b. J Pediatr 1994, 125:581-584.
36. Sinsalo M., Aittoniemi J., Kayhty H., et al. Haemophilus influenzae type b (Hib) antibody concentrations and vaccination responses in patients with chronic lymphocytic leukaemia: predicting factors for response. Leuk Lymphoma 2002, 43:1967-1969.
37. Hartkamp A., Mulder A.H., Rijkers G.T., et al. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine 2001, 19:1671-1677.
38. Elting L.S., Whimbey E., Lo W., et al. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 1995, 3:198-202.
39. Ljungman P., Andersson J., Aschan J., et al. Influenza A in immunocompromised patients. Clin Infect Dis 1993, 17:244-247.
40. Kempe A., Hall C., MacDonald N., et al. Influenza in children with cancer. J Pediatr 1989, 115:33-39.
41. Earle C.C. Influenza vaccination in elderly patients with advanced colorectal cancer. J Clin Oncol 2003, 21:1161-1166.
42. Ring A., Marx G., Steer C., et al. Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. Int J Clin Pract 2003, 57:542-543.
43. Brydak L.B., Rokicka-Milewska R., Jackowska T., et al. Kinetics of humoral response in children with acute lymphoblastic leukemia immunized with influenza vaccine in 1993 in Poland. Leuk Lymphoma 1997, 26:163-169.
44. Brydak L.B., Rokicka-Milewska R., Machala M., et al. Immunogenicity of subunit trivalent influenza vaccine in children with acute lymphoblastic leukemia. Pediatr Infect Dis J 1998, 17:125-129.
45. Chisholm J.C., Devine T., Charlett A., et al. Response to influenza immunisation during treatment for cancer. Arch Dis Child 2001, 84:496-500.
46. Porter C.C., Edwards K.M., Zhu Y., et al. Immune responses to influenza immunization in children receiving maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2004, 42:36-40.
47. Goossen G.M., Kremer L.C., van de Wetering M.D. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev 2009, 2. CD006484.
48. Chisholm J., Howe K., Taj M., et al. Influenza immunisation in children with solid tumours. Eur J Cancer 2005, 41:2280-2287.
49. Anderson H., Petrie K., Berrisford C., et al. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer 1999, 80:219-220.
50. Bate J., Yung C.F., Hoschler K., et al. Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. Clin Infect Dis 2010, 51:e95-e104.
51. Meerveld-Eggink A., de Weerdt O., van der Velden A.M., et al. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol 2011, 22:2031-2035.
52. Mazza J.J., Yale S.H., Arrowood J.R., et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005, 3:214-220.
53. Brydak L.B., Calbecka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leuk Lymphoma 1999, 32:369-374.
54. Brydak L.B., Machala M., Centkowski P., et al. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma. Vaccine 2006, 24:6620-6623.
55. Centkowski P., Brydak L., Machala M., et al. Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. J Clin Immunol 2007, 27:339-346.
56. Lo W., Whimbey E., Elting L., et al. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 1993, 12:778-782.
57. van der Velden A.M., Mulder A.H., Hartkamp A., et al. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. Eur J Intern Med 2001, 12:420-424.
58. Ramanathan R.K., Potter D.M., Belani C.P., et al. Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients. J Clin Oncol 2002, 20:4313-4318.
59. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011, 60:1-64.
60. Fiore A.E., Uyeki T.M., Broder K., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59:1-62.
61. Hammarström V., Pauksen K., Svensson H., et al. Tetanus immunity in patients with haematological malignancies. Supp Care Cancer 1998, 6:469-472.
62. von der Hardt K., Jungert J., Beck J., et al. Humoral immunity against diphtheria, tetanus and poliomyelitis after antineoplastic therapy in children and adolescents: a retrospective analysis. Vaccine 2000, 18:2999-3004.
63. Reinhardt D., Houliara K., Pekrun A., et al. Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer. Scand J Infect Dis 2003, 35:851-857.
64. Ek T., Mellander L., Hahn-Zoric M., Abrahamsson J. Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and Haemophilus influenzae type b. J Pediatr Hematol Oncol 2004, 26:727-734.
65. Nordoy T., Kolstad A., Tuck M., et al. Radioimmunotherapy with iodine-131 Tositumonab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens. Clin Immunol 2001, 100:40-48.
66. Zignol M., Peracchi M., Tridello G., et al. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 2004, 101:635-641.
67. Stenvik M., Hovi L., Siimes M., et al. Antipolio prophylaxis of immunocompromised children during a nationwide oral poliovaccine campaign. Pediatr Infect Dis J 1987, 6:1106-1110.
68. Zuckerman M., Brink N., Kyi M., et al. Exposure of immunocompromised individuals to health-care workers immunized with oral poliovaccine. Lancet 1994, 343:985-986.
69. Goyal S., Pai S.K., Kelkar R., et al. Hepatitis B vaccination in acute lymphoblastic leukemia. Leuk Res 1998, 22:193-195.
70. Somjee S., Pai S., Kelkar R., et al. Hepatitis B vaccination in children with acute lymphoblastic leukemia: results of an intensified immunization schedule. Leuk Res 1999, 23:365-367.
71. Meral A., Sevinir B., Gunay U. Efficacy of immunization against hepatitis B virus infection in children with cancer. Med Pediatr Oncol 2000, 35:47-51.
72. Rokicka-Milewska R., Jackowska T., Sopylo B., et al. Active immunization of children with leukemias and lymphomas against infection by hepatitis B virus. Acta Paediatr Jpn 1993, 35:400-403.
73. Polychronopoulou-Androulakaki S., Panagiotou J.P., Kostaridou S., et al. Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine. Pediatr Hematol Oncol 1996, 13:425-431.
74. Yetgin S., Tunc B., Koc A., et al. Two booster dose hepatitis B virus vaccination in patients with leukemia. Leuk Res 2001, 25:647-649.
75. Takahashi M., Okuno Y., Otsuka T., et al. Development of a live attenuated varicella vaccine. Biken J 1975, 18:25-33.
76. Gershon A., Steinberg S. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989, 320:892-897.
77. Brunell P., Geiser C., Novelli V., et al. Varicella-like illness caused by live varicella vaccine in children with acute lymphocytic leukemia. Pediatrics 1987, 79:922-927.
78. Adler A.L., Casper C., Boeckh M., et al. An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients. Infect Control Hosp Epidemiol 2008, 29:866-870.
79. Lawrence R., Gershon A., Holzman R., et al. The risk for zoster after varicella vaccination in children with leukemia. N Engl J Med 1988, 318:543-548.
80. Hardy I., Gershon A., Steinberg S., et al. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia Varicella Vaccine Collaborative Group. N Engl J Med 1991, 325:1545-1550.
81. Cristofani L., Weinberg A., Peixoto V., et al. Administration of live attenuated varicella vaccine to children with cancer before starting chemotherapy. Vaccine 1991, 9:873-876.
82. Diaz P., Au D., Smith S., et al. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 1991, 87:166-170.
83. Kaplan L., Daum R., Smaron M., et al. Severe measles in immunocompromised patients. JAMA 1992, 267:1237-1241.
84. Nilsson A., De Milito A., Engstrom P., et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002, 109:e91.
85. Lum L. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987, 69:369-380.
86. Lum L., Munn N., Schanfield M., et al. The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood 1986, 67:582-587.
87. Lum L., Noges J., Beatty P., et al. Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts. Bone Marrow Transplant 1988, 3:399-406.
88. Lum L., Seigneuret M., Storb R. The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. J Clin Immunol 1986, 6:389-396.
89. Saxon A., Mitsuyaso R., Stevens R., et al. Transfer of specific immune responses after bone marrow transplantation. J Clin Invest 1986, 78:959-967.
90. Wahren B., Gahrton G., Linde A., et al. Transfer and persistence of viral antibody-producing cells in bone marrow transplantation. J Infect Dis 1984, 150:358-365.
91. Ljungman P., Duraj V., Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991, 7:89-93.
92. Ljungman P., Wiklund H.M., Duraj V., et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990, 162:496-500.
93. Engelhard D., Handsher R., Naparstek E., et al. Immune responses to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 1991, 8:295-300.
94. Ljungman P., Fridell E., Lönnqvist B., et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989, 159:610-615.
95. Ljungman P., Lewensohn-Fuchs I., Hammarstrom V., et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood 1994, 84:657-663.
96. Ilan Y., Nagler A., Adler R., et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 1993, 18:246-252.
97. Guinan E.C., Molrine D.C., Antin J.H., et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994, 57:677-684.
98. Wimperis J., Brenner M., Prentice H., et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986, 1:339-343.
99. Gerritsen E., Van Tol M., Van't Veer M., et al. Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation. Blood 1994, 84:4374-4382.
100. Storek J., Dawson M.A., Lim L.C., et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplant 2004, 33:337-346.
101. Engelhard D., Cordonnier C., Shaw P.J., et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 2002, 117:444-450.
102. Nichols W.G., Guthrie K.A., Corey L., et al. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004, 39:1300-1306.
103. Ljungman P., Ward K.N., Crooks B.N., et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001, 28:479-484.
104. Erard V., Wald A., Corey L., et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007, 196:266-270.
105. Ljungman P., Cordonnier C., Einsele H., et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009, 44:521-526.
106. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
107. Cordonnier C., Bernaudin J.F., Bierling P., et al. Pulmonary complications occurring after allogeneic bone marrow transplantation. A study of 130 consecutive transplanted patients. Cancer 1986, 58:1047-1054.
108. Aucouturier P., Barra A., Intrator L., et al. Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. Blood 1987, 70:779-785.
109. Winston D.J., Schiffman G., Wang D.C., et al. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med 1979, 91:835-841.
110. Avanzini M., Carra A., Macccario R., et al. Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. J Clin Immunol 1995, 15:137-144.
111. Barra A., Cordonnier C., Preziosi M.P., et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 1992, 166:1021-1028.
112. Hammarström V., Pauksen K., Azinge J., et al. The influence of graft versus host reaction on the response to pneumococcal vaccination in bone marrow transplant patients. Support Care Cancer 1993, 1:195-199.
113. Lortan J., Vellodi A., Jurges E., et al. Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation. Clin Exp Immunol 1992, 88:512-519.
114. Spoulou V., Victoratos P., Ioannidis J.P., et al. Kinetics of antibody concentration and avidity for the assessment of immune response to pneumococcal vaccine among children with bone marrow transplants. J Infect Dis 2000, 182:965-969.
115. Parkkali T., Kayhty H., Anttila M., et al. IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines. Bone Marrow Transplant 1999, 24:671-678.
116. Kumar D., Chen M.H., Welsh B., et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 2007, 45:1576-1582.
117. Molrine D.C., Antin J.H., Guinan E.C., et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003, 101:831-836.
118. Cordonnier C., Labopin M., Chesnel V., et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 2009, 48:1392-1401.
119. Cordonnier C., Labopin M., Jansen K.U., et al. Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant. Bone Marrow Transplant 2010, 45:1423-1426.
120. Cordonnier C., Labopin M., Chesnel V., et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine 2010, 28:2730-2734.
121. Meerveld-Eggink A., van der Velden A.M., Ossenkoppele G.J., et al. Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:1523-1530.
122. Meisel R., Kuypers L., Dirksen U., et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007, 109:2322-2326.
123. Pao M., Papadopoulos E.B., Chou J., et al. Response to pneumococcal (PNCRM7) and Haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 2008, 14:1022-1030.
124. Ljungman P., Small T.N. Vaccination of SCT recipients. Bone Marrow Transplant 2011, 46:621. Vaccination Recommendations Writing Group.
125. Ljungman P., Small T.N. Update to vaccination guidelines. Biol Blood Marrow Transplant 2010, 16:1608-1609.
126. Parkkali T., Kayhty H., Ruutu T., et al. A comparison of early and late vaccination with Haemophilus Influenzae type B conjugate and pneumococcal polysaccaride vaccines after allogeneic BMT. Bone Marrow Transplant 1996, 18:961-967.
127. Avanzini M.A., Carra A.M., Maccario R., et al. Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls. J Clin Immunol 1998, 18:193-201.
128. Molrine D., Guinan E., Antin J., et al. Donor immunization with Haemophilus influenzae type B (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood 1996, 87:3012-3018.
129. Aschan J., Ringden O., Ljungman P., et al. Influenza B in transplant patients. Scand J Infect Dis 1989, 21:349-350.
130. Whimbey E., Elting L.S., Couch R.B., et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994, 13:437-440.
131. Engelhard D., Nagler A., Hardan I., et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993, 11:1-5.
132. Pauksen K., Linde A., Hammarstrom V., et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis 2000, 30:342-348.
133. Issa N.C., Marty F.M., Gagne L.S., et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011, 17:434-438.
134. Engelhard D., Zakay-Rones Z., Shapira M.Y., et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine 2011, 29:1777-1782.
135. Avetisyan G., Aschan J., Hassan M., et al. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008, 86:257-263.
136. Avetisyan G., Ragnavolgyi E., Toth G.T., et al. Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients. Bone Marrow Transplant 2005, 36:411-415.
137. Machado C.M., Cardoso M.R., da Rocha I.F., et al. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant 2005, 36:897-900.
138. Jaffe D., Papadopoulos E., Young J., et al. Immunogeneicyt of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 2006, 108:2470-2475.
139. Idilman R., Ustun C., Karayalcin S., et al. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation. Clin Transplant 2003, 17:438-443.
140. Ilan Y., Nagler A., Zeira E., et al. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients. Bone Marrow Transplant 2000, 26:633-638.
141. Brugger S., Oesterreicher C., Hofmann H., et al. Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunized donor. Lancet 1997, 349:996-997.
142. Ilan Y., Nagler A., Adler R., et al. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 1993, 104:1818-1821.
143. Onozawa M., Hashino S., Darmanin S., et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008, 14:1226-1230.
144. Parkkali T., Stenvik M., Ruutu T., et al. Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT. Bone Marrow Transplant 1997, 20:663-668.
145. Parkkali T., Sjölander R.-M., Ruutu T., et al. A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT. Bone Marrow Transplant 1997, 19:933-938.
146. Ljungman P., Aschan J., Gustafsson B., et al. Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplant 2004, 34:1067-1069.
147. Florax A., Ehlert K., Becker K., et al. Bordetella pertussis respiratory infection following hematopoietic stem cell transplantation: time for universal vaccination?. Bone Marrow Transplant 2006, 38:639-640.
148. Kochethu G., Clark F., Craddock C. Pertussis: should we vaccinate post transplant?. Bone Marrow Transplant 2006, 37:793-794.
149. Papadopoulos E., Young J., Kernan N., et al. Use of the tetanus toxoid, reduced dose diphtheria and pertussis vaccine (Tdap) in allogeneic transplant (alloHCT) recipients. Blood 2008, 112:2214.
150. Kharfan-Dabaja M., Boeckh M., Wilck M., et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, Jan 9 (e-pub ahead of print).
151. Wloch M.K., Smith L.R., Boutsaboualoy S., et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008, 197:1634-1642.
152. Parkkali T., Kayhty H., Lehtonen H., et al. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. Bone Marrow Transplant 2001, 27:79-84.
153. Tsolia M., Gershon A.A., Steinberg S.P., et al. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr 1990, 116:184-189.
154. Sauerbrei A., Prager J., Hengst U., et al. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997, 20:381-383.
155. Redman R., Nader S., Zerboni L., et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997, 178:578-585.
156. Erard V., Guthrie K.A., Varley C., et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus (VZV) disease following hematopoietic cell transplantation: no evidence of rebound VZV disease after drug discontinuation. Blood 2007, 110:3071-3077.
157. Machado C.M., Goncalves F.B., Pannuti C.S., et al. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo Brazil. Blood 2002, 99:83-87.
158. Ljungman P., Aschan J., Barkholt L., et al. Measles immunity after allogeneic stem cell transplantation: influence of donor type, graft type, intensity of conditioning, and graft-versus host disease. Bone Marrow Transplant 2004, 34:589-593.
159. Nakano T., Shimono Y., Sugiyama K., et al. Clinical features of measles in immunocompromised children. Acta Paediatr Jpn 1996, 38:212-217.
160. Patel S.R., Ortin M., Cohen B.J., et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis 2007, 44:625-634.
161. Machado C.M., de Souza V., Sumita L.M., et al. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant 2005, 35:787-791.
162. King S.M., Saunders E.F., Petric M., et al. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996, 17:633-636.
163. Spoulou V., Giannaki M., Vounatsou M., et al. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. Bone Marrow Transplant 2004, 33:1187-1190.
164. Bakshi N., Lawson J., Hanson R., et al. Fatal mumps meningoencephalitis in a child with severe combined immunodeficiency after bone marrow transplantation. J Child Neurol 1996, 11:159-162.
165. Rio B., Marjanovic Z., Lévy V., et al. Vaccination for yellow fever after bone marrow transplantation. Bone Marrow Transplant 1996, 17(suppl 1):95.
166. Hammarström V., Pauksen K., Björkstrand B., et al. Tetanus immunity in autologus bone marrow and blood stem cell transplant patients. Bone Marrow Transplant 1998, 22:67-72.
167. Pauksen K., Hammarström V., Ljungman P., et al. Immunity to poliovirus and immunization with inactivated poliovaccine after autologous bone marrow transplantation. Clin Infect Dis 1994, 18:547-552.
168. Pauksen K., Duraj V., Ljungman P., et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant 1992, 9:427-432.
169. Nordoy T., Husebekk A., Aaberge I.S., et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT: serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant 2001, 28:681-687.
170. Gandhi M.K., Egner W., Sizer L., et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant 2001, 28:775-781.
171. Antin J.H., Guinan E.C., Avigan D., et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:213-222.
172. Molrine D., Guinan E., Antin J., et al. Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Bone Marrow Transplant 1996, 17:1149-1155.
173. Small T.N., Zelenetz A.D., Noy A., et al. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:1538-1542.
174. Hata A., Asanuma H., Rinki M., et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002, 347:26-34.
175. Ljungman P., Wang F.Z., Nilsson C., et al. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study. Support Care Cancer 2003, 11:739-741.
176. Danzinger-Isakov L., Kumar D. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009, 9(suppl 4):S258-S262.
177. Burroughs M., Moscona A. Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis 2000, 30:857-869.
178. Campbell A.L., Herold B.C. Immunization of pediatric solid-organ transplantation candidates: immunizations in transplant candidates. Pediatr Transplant 2005, 9:652-661.
179. Kumar D., Humar A., Plevneshi A., et al. Invasive pneumococcal disease in solid organ transplant recipients: 10-year prospective population surveillance. Am J Transplant 2007, 7:1209-1214.
180. Furth S.L., Neu A.M., Case B., et al. Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration. J Pediatr 1996, 128:99-101.
181. Linnemann C.C., First M.R., Schiffman G. Response to pneumococcal vaccine in renal transplant and hemodialysis patients. Arch Intern Med 1981, 141:1637-1640.
182. Linnemann C.C., First M.R. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med 1986, 146:1554-1556.
183. Furth S., Neu A., Case B., et al. Pneumococcal polysaccaride vaccine in children with chronic renal disease: a prospective study of antibody response and duration. J Pediatr 1996, 128:99-101.
184. Dengler T., Strnad N., Zimmermann R., et al. Pneumococcal vaccination after heart and liver transplantation: immune responses in immunosuppressed patients and in healthy controls. Dtsch Med Wochenschr 1996, 121:1519-1525.
185. Dengler T.J., Strnad N., Buhring I., et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 1998, 66:1340-1347.
186. Kazancioglu R., Sever M.S., Yuksel-Onel D., et al. Immunization of renal transplant recipients with pneumococcal polysaccharide vaccine. Clin Transplant 2000, 14:61-65.
187. Blumberg E.A., Brozena S.C., Stutman P., et al. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis 2001, 32:307-310.
188. McCashland T.M., Preheim L.C., Gentry M.J. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000, 181:757-760.
189. Kruger S., Muller-Steinhardt M., Kirchner H., et al. A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients. Am J Kidney Dis 2001, 38:1264-1270.
190. Lin P.L., Michaels M.G., Green M., et al. Safety and immunogenicity of the American Academy of Pediatrics-recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 2005, 116:160-167.
191. Barton M., Wasfy S., Dipchand A.I., et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity. Pediatr Infect Dis J 2009, 28:688-692.
192. Kumar D., Rotstein C., Miyata G., et al. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003, 187:1639-1645.
193. Kumar D., Welsh B., Siegal D., et al. Immunogenicity of pneumococcal vaccine in renal transplant recipients: three year follow-up of a randomized trial. Am J Transplant 2007, 7:633-638.
194. Kumar D., Chen M.H., Wong G., et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis 2008, 47:885-892.
195. Duchini A., Hendry R.M., Redfield D.C., et al. Influenza infection in patients before and after liver transplantation. Liver Transpl 2000, 6:531-542.
196. Sanchez-Fructuoso A.I., Prats D., Naranjo P., et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation 2000, 69:436-439.
197. Versluis D., Beyer W., Masurel N., et al. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 1986, 42:376-379.
198. Duchini A., Hendry R.M., Nyberg L.M., et al. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl 2001, 7:311-313.
199. Soesman N.M., Rimmelzwaan G.F., Nieuwkoop N.J., et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 2000, 61:85-93.
200. Fraund S., Wagner D., Pethig K., et al. Influenza vaccination in heart transplant recipients. J Heart Lung Transplant 1999, 18:220-225.
201. Hayney M.S., Welter D.L., Francois M., et al. Influenza vaccine antibody responses in lung transplant recipients. Prog Transplant 2004, 14:346-351.
202. Manuel O., Pascual M., Hoschler K., et al. Humoral response to the influenza a H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011, 52:248-256.
203. Altamirano-Diaz L., West L., Humar A., et al. Early post-transplant vaccination with pandemic influenza A/H1N1 vaccine in pediatric heart transplant recipients. Pediatr Transplant 2011, 15:172-175.
204. Gaeta G.B., Pariani E., Amendola A., et al. Influenza vaccination in patients with cirrhosis and in liver transplant recipients. Vaccine 2009, 27:3373-3375.
205. Edvardsson V.O., Flynn J.T., Deforest A., et al. Effective immunization against influenza in pediatric renal transplant recipients. Clin Transplant 1996, 10(6 pt 1):556-560.
206. Mauch T., Crouch N., Freese D., et al. Antibody response of pediatric solid organ transplant recipients to immunization against influenza virus. J Pediatr 1995, 127:957-960.
207. Furth S., Neu A., McColley S., et al. Immune response to influenza vaccination in children with renal disease. Pediatr Nephrol 1995, 9:566-568.
208. Hojsak I., Avitzur Y., Mor E., et al. Antibody response to influenza vaccine in pediatric liver transplant recipients. Pediatr Infect Dis J 2011, 30:491-494.
209. Morelon E., Noble C.P., Daoud S., et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine 2010, 28:6885-6890.
210. Mazzone P.J., Mossad S.B., Mawhorter S.D., et al. Cell-mediated immune response to influenza vaccination in lung transplant recipients. J Heart Lung Transplant 2004, 23:1175-1181.
211. Madan R.P., Tan M., Fernandez-Sesma A., et al. A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings. Clin Infect Dis 2008, 46:712-718.
212. Candon S., Thervet E., Lebon P., et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant 2009, 9:2346-2354.
213. Magnani G., Falchetti E., Pollini G., et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 2005, 24:588-592.
214. Goldschmidt I., Pfister E.D., Becker M., et al. Acceptance and adverse events of the 2009 H1N1 vaccination in immunosuppressed pediatric liver transplant recipients. J Pediatr 2011, 158:329-333.
215. Lawal A., Basler C., Branch A., et al. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant 2004, 4:1805-1809.
216. Sánchez-Fueyo A., Rimola A., Grande L., et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000, 31:496-501.
217. Kimball P., Verbeke S., Flattery M., et al. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation 2000, 69:2449-2451.
218. Burbach G., Bienzle U., Stark K., et al. Influenza vaccination in liver transplant recipients. Transplantation 1999, 67:753-755.
219. Blumberg E.A., Fitzpatrick J., Stutman P.C., et al. Safety of influenza vaccine in heart transplant recipients. J Heart Lung Transplant 1998, 17:1075-1080.
220. Fabio V., Daniele F., Monica D.D., et al. Pancreas rejection after pandemic influenzavirus A(H1N1) vaccination or infection: a report of two cases. Transpl Int 2011, 24:e28-e29. doi:10.1111/j.1432-2277.2010.01193.x.
221. Swedish Medical Products Agency. Avslutande sammanställning av inrapporterade biverkningar av Pandemrix under perioden oktober 2009-mitten av april 2010. http://www.lakemedelsverket.se/upload/nyheter/2010/2010-05-04-sammanstallning-pandemrix.pdf.
222. Danziger-Isakov L., Cherkassky L., Siegel H., et al. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation 2010, 89:838-844.
223. Kruger S., Seyfarth M., Sack K., et al. Defective immune response to tetanus toxoid in hemodialysis patients and its association with diphtheria vaccination. Vaccine 1999, 17:1145-1150.
224. Enke B.U., Bokenkamp A., Offner G., et al. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. Transplantation 1997, 64:237-241.
225. Barcena Marugan R., Garcia-Hoz F., Vazquez Romero M., et al. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 2002, 97:2398-2401.
226. Crosnier J., Junges P., Courouce A.-M., et al. Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units II: haemodialysis patients. Lancet 1981, 2:797-800.
227. Stevens C., Alter H., Taylor P., et al. Hepatitis B virus vaccine in patients receiving hemodialysis: immunogenecity and efficacy. N Engl J Med 1984, 311:496-501.
228. Van Thiel D., el-Ashmawy L., Love K., et al. Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci 1992, 37:1245-1249.
229. Villeneuve E., Vincelette J., Villeneuve J.P. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000, (14(suppl B)):59B-62B.
230. Arslan M., Wiesner R.H., Sievers C., et al. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001, 7:314-320.
231. Horlander J.C., Boyle N., Manam R., et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999, 318:304-307.
232. Dominguez M., Barcena R., Garcia M., et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000, 6:440-442.
233. Engler S.H., Sauer P.W., Golling M., et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol 2001, 13:363-367.
234. Aziz A., Aziz S., Li D.S., et al. Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease. J Viral Hepat 2006, 13:217-221.
235. Arslan M., Wiesner R.H., Poterucha J.J., et al. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001, 72:272-276.
236. Sokal E., Ulla L., Otte J. Hepatitis B vaccine response before and after transplantation in 55 extrahepatic biliary atresia children. Dig Dis Sci 1992, 37:1250-1252.
237. Wagner D., Wagenbreth I., Stachan-Kunstyr R., et al. Failure of vaccination against hepatitis B with Gen H-B-Vax-D in immunosuppressed heart transplant patients. J Infect Dis 1992, 166:1021-1028.
238. Wagner D., Wagenbreth J., Stachan-Kunstyr R., et al. Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products. Clin Investig 1994, 72:240-352.
239. Duca P., Del Pont J.M., D'Agostino D. Successful immune response to a recombinant hepatitis B vaccine in children after liver transplantation. J Pediatr Gastroenterol Nutr 2001, 32:168-170.
240. Angelico M., Di Paolo D., Trinito M.O., et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002, 35:176-181.
241. Choy B.Y., Peiris J.S., Chan T.M., et al. Immunogenicity of intradermal hepatitis B vaccination in renal transplant recipients. Am J Transplant 2002, 2:965-969.
242. Lo C.M., Liu C.L., Chan S.C., et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005, 43:283-287.
243. Karasu Z., Ozacar T., Akarca U., et al. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat 2005, 12:212-215.
244. Starkel P., Stoffel M., Lerut J., et al. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl 2005, 11:1228-1234.
245. Bienzle U., Gunther M., Neuhaus R., et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003, 38:811-819.
246. Gunther M., Neuhaus R., Bauer T., et al. Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. Liver Transpl 2006, 12:316-319.
247. Dumot J.A., Barnes D.S., Younossi Z., et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999, 94:1601-1604.
248. Ferreira C.T., da Silveira T.R., Vieira S.M., et al. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol Nutr 2003, 37:258-261.
249. Arslan M., Wiesner R.H., Poterucha J.J., et al. Hepatitis A antibodies in liver transplant recipients: evidence for loss of immunity posttransplantation. Liver Transpl 2000, 6:191-195.
250. Gunther M., Stark K., Neuhaus R., et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 2001, 71:477-479.
251. Plotkin S.A., Higgins R., Kurtz J.B., et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994, 58:1176-1178.
252. Plotkin S.A., Starr S.E., Friedman H.M., et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann Intern Med 1991, 114:525-531.
253. Griffiths P.D., Stanton A., McCarrell E., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
254. Dengler T.J., Zimmermann R., Meyer J., et al. Vaccination against tick-borne encephalitis under therapeutic immunosuppression: reduced efficacy in heart transplant recipients. Vaccine 1999, 17:867-874.
255. Lynfield R., Herrin J.T., Rubin R.H. Varicella in pediatric renal transplant recipients. Pediatrics 1992, 90(2 pt 1):216-220.
256. Broyer M., Boudailliez B. Varicella vaccine in children with chronic renal insufficiency. Postgrad Med J 1985, 61(suppl 4):103-106.
257. Broyer M., Tete M.J., Guest G., et al. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997, 99:35-39.
258. Furth S.L., Hogg R.J., Tarver J., et al. Varicella vaccination in children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 2003, 18:33-38.
259. Nithichaiyo C., Chongsrisawat V., Hutagalung Y., et al. Immunogenicity and adverse effects of live attenuated varicella vaccine (Oka-strain) in children with chronic liver disease. Asian Pac J Allergy Immunol 2001, 19:101-105.
260. Kano H., Mizuta K., Sakakihara Y., et al. Efficacy and safety of immunization for pre- and post-liver transplant children. Transplantation 2002, 74:543-550.
261. Zamora I., Simon J.M., Da Silva M.E., et al. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994, 8:190-192.
262. Weinberg A., Horslen S.P., Kaufman S.S., et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006, 6:565-568.
263. Khan S., Erlichman J., Rand E.B. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 2006, 10:78-82.
264. Chaves Tdo S., Lopes M.H., de Souza V.A., et al. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant 2005, 9:192-196.
265. Levitsky J., Te H.S., Faust T.W., et al. Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant 2002, 2:880-882.
266. Kraft J.N., Shaw J.C. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol 2006, 142:943-945.
267. Flynn J.T., Frisch K., Kershaw D.B., et al. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Adv Perit Dial 1999, 15:269-272.
268. Mori K., Kawamura K., Honda M., et al. Responses in children to measles vaccination associated with perirenal transplantation. Pediatr Int 2009, 51:617-620.
269. Kirkpatrick C.H. Specific polysaccharide antibody deficiency. Ann Allergy Asthma Immunol 2006, 97:271.
270. Tedesco F. Inherited complement deficiencies and bacterial infections. Vaccine 2008, 26(suppl 8):13-18.
271. Andreoni J., Kayhty H., Densen P. Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals. J Infect Dis 1993, 168:227-231.
272. Biselli R., Casapollo I., D'Amelio R., et al. Antibody response to meningococcal polysaccharides A and C in patients with complement defects. Scand J Immunol 1993, 37:644-650.
273. Drogari-Apiranthitou M., Fijen C.A., Van De Beek D., et al. Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients. Clin Exp Immunol 2000, 119:311-316.
274. Fijen C.A., Kuijper E.J., Drogari-Apiranthitou M., et al. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1998, 114:362-369.
275. Platonov A.E., Beloborodov V.B., Pavlova L.I., et al. Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1995, 100:32-39.
276. Platonov A.E., Vershinina I.V., Kuijper E.J., et al. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 2003, 21:4437-4447.
277. Soderstrom C., Braconier J.H., Kayhty H., et al. Immune response to tetravalent meningococcal vaccine: opsonic and bactericidal functions of normal and properdin deficient sera. Eur J Clin Microbiol Infect Dis 1989, 8:220-224.
278. Schubert R., Reichenbach J., Rose M., et al. Immunogenicity of the seven valent pneumococcal conjugate vaccine in patients with ataxia-telangiectasia. Pediatr Infect Dis J 2004, 23:269-270.
279. Sanal O., Ersoy F., Tezcan I., et al. Antibody response to a seven-valent pneumococcal conjugated vaccine in patients with ataxia-telangiectasia. J Clin Immunol 2004, 24:411-417.
280. Stray-Pedersen A., Aaberge I.S., Fruh A., et al. Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine: immunogenicity in patients with ataxia-telangiectasia. Clin Exp Immunol 2005, 140:507-516.
281. Walter N.D., Taylor T.H., Shay D.K., et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis 2010, 50:175-183.
282. Jansen A.G., Sanders E.A., van der Ende A., et al. Invasive pneumococcal and meningococcal disease: association with influenza virus and respiratory syncytial virus activity?. Epidemiol Infect 2008, 136:1448-1454.
283. Immunization in Special Clinical Circumstances. Red Book report of the Committee on Infectious Diseases 2009, American Academy of Pediatrics, Elk Grove Village, IL. 28th ed. L.K. Pickering (Ed.).
284. Zhang S.Y., Boisson-Dupuis S., Chapgier A., et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008, 226:29-40.
285. Dupuis S., Jouanguy E., Al-Hajjar S., et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 2003, 33:388-391.
286. Kawashima H., Hasegawa D., Nakamura M., et al. Hazards of early BCG vaccination: BCGitis in a patient with chronic granulomatous disease. Pediatr Int 2007, 49:418-419.
287. Kobayashi Y., Komazawa Y., Kobayashi M., et al. Presumed BCG infection in a boy with chronic granulomatous disease: a report of a case and a review of the literature. Clin Pediatr (Phila) 1984, 23:586-589.
288. Kusuhara K., Ohga S., Hoshina T., et al. Disseminated bacillus Calmette-Guerin lymphadenitis in a patient with gp91phox- chronic granulomatous disease 25 years after vaccination. Eur J Pediatr 2009, 168:745-747.
289. Smith P.A., Wittenberg D.F. Disseminated BCG infection in a child with chronic granulomatous disease: a case report. S Afr Med J 1984, 65:821-822.
290. Mansouri D., Adimi P., Mirsaeidi M., et al. Inherited disorders of the IL-12-IFN-gamma axis in patients with disseminated BCG infection. Eur J Pediatr 2005, 164:753-757.
291. Dai Y.S., Liang M.G., Gellis S.E., et al. Characteristics of mycobacterial infection in patients with immunodeficiency and nuclear factor-kappaB essential modulator mutation, with or without ectodermal dysplasia. J Am Acad Dermatol 2004, 51:718-722.
292. Orange J.S., Jain A., Ballas Z.K., et al. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J Allergy Clin Immunol 2004, 113:725-733.
293. Winkelstein J.A., Marino M.C., Johnston R.B., et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 2000, 79:155-169.
294. Pasic S., Lilic D., Pejnovic N., et al. Disseminated bacillus Calmette-Guerin infection in a girl with hyperimmunoglobulin E syndrome. Acta Paediatr 1998, 87:702-704.
295. Pasic S. Local bacillus Calmette-Guerin infection in hyperimmunoglobulin-E syndrome. Acta Paediatr 2002, 91:1271-1272.
296. Shrimpton A., Duddridge M., Ziegler-Heitbrock L. Vaccination with polysaccharide-conjugate-vaccines in adult patients with specific antibody deficiency. Vaccine 2006, 24:3574-3580.
297. Rezaei N., Aghamohammadi A., Read R.C. Response to polysaccharide vaccination amongst pediatric patients with common variable immunodeficiency correlates with clinical disease. Iran J Allergy Asthma Immunol 2008, 7:231-234.
298. Ko J., Radigan L., Cunningham-Rundles C. Immune competence and switched memory B cells in common variable immunodeficiency. Clin Immunol 2005, 116:37-41.
299. Goldacker S., Draeger R., Warnatz K., et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 2007, 124:294-303.
300. Asindi A.A., Bell E.J., Browning M.J., et al. Vaccine-induced polioencephalomyelitis in Scotland. Scott Med J 1988, 33:306-307.
301. Inaba H., Hori H., Ito M., et al. Polio vaccine virus-associated meningoencephalitis in an infant with transient hypogammaglobulinemia. Scand J Infect Dis 2001, 33:630-631.
302. Martin J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals 2006, 34:117-122.
303. Ermolovich M.A., Fel'dman E.V., Samoilovich E.O., et al. Characterization of the immune status of patients with vaccine-associated poliomyelitis. Zh Mikrobiol Epidemiol Immunobiol 2002, 2:42-50.
304. Mihatsch M.J., Ohnacker H., Just M., et al. Lethal measles giant cell pneumonia after live measles vaccination in a case of thymic alymphoplasia Gitlin. Helv Paediatr Acta 1972, 27:143-146.
305. Monafo W.J., Haslam D.B., Roberts R.L., et al. Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr 1994, 124:273-276.
306. Schuil J., van de Putte E.M., Zwaan C.M., et al. Retinopathy following measles, mumps, and rubella vaccination in an immuno-incompetent girl. Int Ophthalmol 1998, 22:345-347.
307. Patel N.C., Hertel P.M., Estes M.K., et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010, 362:314-319.
308. Werther R.L., Crawford N.W., Boniface K., et al. Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency. J Allergy Clin Immunol 2009, 124:600.
309. Azzari C., Gambineri E., Resti M., et al. Safety and immunogenicity of measles-mumps-rubella vaccine in children with congenital immunodeficiency (DiGeorge syndrome). Vaccine 2005, 23:1668-1671.
310. Moylett E.H., Wasan A.N., Noroski L.M., et al. Live viral vaccines in patients with partial DiGeorge syndrome: clinical experience and cellular immunity. Clin Immunol 2004, 112:106-112.
311. Perez E.E., Bokszczanin A., McDonald-McGinn D., et al. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 2003, 112:e325.
312. Klippel J.H., Karsh J., Stahl N.I., et al. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum 1979, 22:1321-1325.
313. Elkayam O., Paran D., Caspi D., et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002, 34:147-153.
314. Battafarano D.F., Battafarano N.J., Larsen L., et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998, 41:1828-1834.
315. Elkayam O., Paran D., Burke M., et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity 2005, 38:493-496.
316. Kapetanovic M.C., Saxne T., Sjoholm A., et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:106-111.
317. Mease P.J., Ritchlin C.T., Martin R.W., et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004, 31:1356-1361.
318. Bingham C.O., Looney R.J., Deodhar A., et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62:64-74.
319. Herron A., Dettleff G., Hixon B., et al. Influenza vaccination in patients with rheumatic diseases: safety and efficacy. JAMA 1979, 242:53-56.
320. Williams G.W., Steinberg A.D., Reinertsen J.L., et al. Influenza immunization in systemic lupus eruthematosus: a double-blind trial. Ann Intern Med 1978, 88:729-734.
321. Louie J.S., Nies K.M., Shoji K.T., et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978, 88:790-792.
322. Elkayam O., Bashkin A., Mandelboim M., et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010, 39:442-447.
323. van Assen S., Holvast A., Benne C.A., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81.
324. Lu C.C., Wang Y.C., Lai J.H., et al. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine 2011, 29:444-450.
325. Abu-Shakra M., Zalmanson S., Neumann L., et al. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol 2000, 27:1681-1685.
326. Del Porto F., Lagana B., Biselli R., et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis: safety and immunogenicity. Vaccine 2006, 24:3217-3223.
327. Kanakoudi-Tsakalidou F., Trachana M., Pratsidou-Gertsi P., et al. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001, 19:589-594.
328. Lu Y., Jacobson D.L., Ashworth L.A., et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009, 104:444-453.
329. Mamula P., Markowitz J.E., Piccoli D.A., et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:851-856.
330. Elkayam O., Yaron M., Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002, 61:623-625.
331. Zonneveld-Huijssoon E., Ronaghy A., Van Rossum M.A., et al. Safety and efficacy of meningococcal C vaccination in juvenile idiopathic arthritis. Arthritis Rheum 2007, 56:639-646.
332. Pileggi G.S., de Souza C.B., Ferriani V.P. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (Hoboken) 2010, 62:1034-1039.
333. Ying X.H., Wagle A.M., Tan L., et al. A rare case of herpes zoster ophthalmicus with complete ophthalmoplegia. J Am Geriatr Soc 2008, 56:2160-2162.
334. Stephens M.C., Shepanski M.A., Mamula P., et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003, 98:104-111.
335. Strangfeld A., Listing J., Herzer P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301:737-744.
336. Shale M.J. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull 2009, 92:61-77.
337. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
338. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
339. Harpaz R., Ortega-Sanchez I.R., Seward J.F. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57(RR-5):1-30.
340. Naqvi A., Fadoo Z., Alvi S. Vaccination guidelines for children with cancer and hematopoietic stem cell transplantation living in resource-poor countries. Pediatr Blood Cancer 2010, 54:3-7.